ImmuPharma plc (LON:IMM – Get Free Report) shares fell 11.1% during trading on Monday . The company traded as low as GBX 5.12 and last traded at GBX 5.33. 5,805,025 shares traded hands during trading, a decline of 24% from the average session volume of 7,604,917 shares. The stock had previously closed at GBX 6.
ImmuPharma Trading Down 11.2%
The stock has a market capitalization of £26.79 million, a P/E ratio of -5.99 and a beta of 1.53. The company has a 50-day moving average price of GBX 8.96 and a two-hundred day moving average price of GBX 6.30.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- I Shouldn’t Be Sending You This
- Wall Street Stock picker Names #1 Stock of 2026
- End of America update
- They Laughed at $30. They Won’t Laugh at $70.
- How Long Will $1M Last in Retirement?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
